For patients and families navigating a diagnosis of metastatic ocular melanoma, treatment often involves not only complex therapies but also extended hospital stays that can disrupt daily life. New research from HonorHealth Research Institute offers encouraging news that may help make one promising treatment approach more convenient and comfortable for patients.
The study focused on tumor-infiltrating lymphocyte (TIL) therapy, an innovative form of cellular immunotherapy that uses a patient’s own immune cells to help fight cancer. TIL therapy involves removing immune cells from a tumor, expanding them into billions of cancer-fighting cells in a laboratory, and then infusing them back into the patient.
Before these enhanced immune cells can be returned, patients must undergo a process called lymphodepletion. This short course of chemotherapy clears space within the immune system, helping the newly infused TIL cells function more effectively. Traditionally, lymphodepletion has required patients to remain hospitalized for several days.
Researchers at HonorHealth wanted to determine whether this preparation phase could safely be completed on an outpatient basis. Their findings suggest that it can.
Between early 2024 and early 2025, 13 melanoma patients participated in the study. Twelve patients ultimately received TIL therapy, and 11 of those completed lymphodepletion while remaining at home rather than staying in the hospital. Only two patients required admission during treatment.
The impact was significant. The outpatient approach eliminated a total of 77 inpatient hospital days while maintaining patient safety. Researchers also noted several additional benefits, including reduced healthcare costs, lower risk of hospital-acquired infections, and improved patient satisfaction.
For many families, the most meaningful advantage may be the ability to remain in familiar surroundings during treatment. Patients were able to sleep in their own beds, spend time with loved ones, and maintain a greater sense of normalcy throughout the process.
The study was led by Nurse Practitioner Molly Drought and supervised by Dr. Justin Moser, an ocular melanoma specialist at HonorHealth Research Institute. According to Dr. Moser, lymphodepletion plays a critical role in helping the newly infused immune cells work more effectively, potentially improving long-term treatment outcomes.
While this study was relatively small, the results are encouraging and may help shape how TIL therapy is delivered in the future. As cellular therapies continue to evolve, improving the patient experience is becoming just as important as improving clinical outcomes.
For the ocular melanoma community, advances like these demonstrate that innovation is happening not only in the development of new treatments but also in finding safer, more patient-friendly ways to deliver them.